OpenAI chief executive Sam Altman, who provided the initial $180mn ... which will be tested in an early stage study in Australia this year. It is also working on drugs for rejuvenating blood ...

在被问及是否会考虑发布一些模型权重以及一些研究时，OpenAI首席执行官Sam Altman首次承认：“我个人认为，我们在这里站在了历史的错误一边 ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.

Vaishnaw outlined India’s AI-driven initiatives spanning healthcare, education, agriculture, weather forecasting, disaster ...

The race to increase human life span through ... that’s set to enter an early-stage trial in Australia this year. Some of the investment will come from OpenAI CEO Sam Altman, who also provided ...